Beta Bionics, Inc.(BBNX)Earnings, Financials & Key RatiosBeta Bionics, Inc. (BBNX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's high-burn strategy and reliance on $5.4 million in quarterly stock-based compensation to fund operations, combined with a dwindling $30.2 million cash reserve, present significant dilution and liquidity risks.
Beta Bionics, Inc. (BBNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Beta Bionics, Inc. (BBNX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 21, 2026 | $0.49vs $0.53+7.5% | $28Mvs $27M+2.5% |
| Q1 2026 | Feb 17, 2026 | $0.30vs $0.42+28.6% | $32Mvs $30M+5.7% |
| Q4 2025 | Oct 28, 2025 | $0.33vs $0.45+26.7% | $27Mvs $29M-5.7% |
| Q3 2025 | Jul 29, 2025 | $0.39vs $0.51+23.5% | $23Mvs $22M+6.1% |
Recent stock market news and headlines for Beta Bionics, Inc. (BBNX)
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.
Key metrics vs top competitors for Beta Bionics, Inc. (BBNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.00 | $757.55M | -9.39 | 53.94% | -73.02% | -40.26% | — | |
| $15.43 | $1.06B | -5.08 | 7.93% | -9.2% | -68.29% | — | |
| $161.55 | $11.34B | 46.42 | 30.73% | 10.44% | 21.38% | — | |
| $73.57 | $28.39B | 35.20 | 15.6% | 19.31% | 33.83% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — |
Beta Bionics, Inc. (BBNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Beta Bionics, Inc. (BBNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 21, 2026·SEC
Feb 17, 2026·SEC
Jan 30, 2026·SEC
Get notified when BBNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Beta Bionics, Inc. (BBNX) stock FAQ — growth, dividends, profitability & financials explained
Beta Bionics, Inc. (BBNX) reported $110.2M in revenue for fiscal year 2025. This represents a 61485% increase from $0.2M in 2022.
Beta Bionics, Inc. (BBNX) grew revenue by 53.9% over the past year. This is strong growth.
Beta Bionics, Inc. (BBNX) reported a net loss of $66.4M for fiscal year 2025.
Beta Bionics, Inc. (BBNX) has a return on equity (ROE) of -40.3%. Negative ROE indicates the company is unprofitable.
Beta Bionics, Inc. (BBNX) had negative free cash flow of $50.6M in fiscal year 2025, likely due to heavy capital investments.
